Nocturnal Use of Add-On Medications for Parkinson’s Disease: Post Hoc Analysis of the COSMOS Study
Objective: To assess nighttime use of add-on medications for Parkinson’s disease (PD) in a post hoc analysis of the COSMOS (COmedication Study assessing Mono- and…Pre-treatment with Methanolic Extract Mucuna pruriens Seeds Attenuates Serotonin Gene Depletion, Motor Dysfunction and Anxiogenic Responses in a Rat Model of Parkinsonism
Objective: Investigate neuroprotective and genoprotective effects of methanolic Mucuna pruriens (Mp) seed extract in a paraquat-induced Parkinsonism rat model. Background: Paraquat exposure has been linked…Digital health technology (DHT) derived features as sensitive measures of disease progression in early Parkinson’s disease under stable dopaminergic treatment
Objective: To evaluate the ability of DHT derived features from remotely collected active tests to measure disease progression in individuals with early Parkinson’s disease (PD)…Effect of Istradefylline on Motor and Non-motor Symptoms in Patients with Parkinson’s Disease: the ISTRA ADJUST PD Randomized, Controlled Study
Objective: To examine the effects of istradefylline on motor and non-motor symptoms in Parkinson’s disease (PD) patients with wearing-off phenomena. Background: Previous results [1,2] of…Continuous Dopaminergic Stimulation-based Levodopa Treatment in Early to Mid-stage Parkinson’s Disease Patients: A Systematic Review and Meta-analysis
Objective: To compare the clinical effectiveness between continuous dopaminergic stimulation (CDS)-based and intermittent levodopa (IL) treatment in patients with early to mid-stage Parkinson’s disease (PD).…Dopa-responsive ataxia with compound heterozygous variants in MRE11
Objective: To evaluate the role for levodopa in patients with ataxia telangiectasia like disorder (ATLD) who have a compound heterozygous mutation in MRE11. Background: Early-onset…Efficacy and Safety of Foslevodopa/Foscarbidopa in People With Parkinson’s Disease With and Without Care Partner Support
Objective: To assess the efficacy and safety of foslevodopa/foscarbidopa (LDp/CDp) in people with Parkinson’s (PwP) with and without care partner support. Background: The progression of…An observational study of the efficacy, safety, and discontinuation rate of foslevodopa/foscarbidopa in 22 patients with advanced Parkinson’s disease
Objective: The aim of this observational study for PD patients treated with foslevodopa/foscarbidopa(LDP/CDP) is to evaluate clinical characteristics, therapeutic efficacy and safety, and to determine…Altered EEG Theta Activity Characterizes Parkinson’s disease with Levodopa-induced Dyskinesia
Objective: We explored the relationship between the build-up and the downscaling process in patients with Parkinson’s disease by analyzing theta frequency spectral bands. Background: During…Impact of IPX203 on Parkinson’s patients’ motor states upon awakening: analysis of patient diary data
Objective: To evaluate “On” upon awakening in Parkinson’s disease patients taking IPX203 in the RISE-PD phase 3 clinical trial. Background: IPX203 is a novel extended-release,…
- 1
- 2
- 3
- …
- 57
- Next Page »